The usefulness and challenges of transgenic mouse models in the study of Alzheimer's disease

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 4, 2010, Pages 386-394

  Wilcock, Donna M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Amyloid; Amyloid precursor protein; Neurodegeneration; Neurofibrillary tangles; Transgenic

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BMS 708163; FLURBIPROFEN; GAMMA SECRETASE INHIBITOR; LITHIUM; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; SEMAGACESTAT; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CELL LOSS; COGNITIVE DEFECT; DRUG DOSE TITRATION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; MENINGOENCEPHALITIS; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; TRANSGENIC MOUSE; AMYLOID PLAQUE; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM; MOUSE; NERVE CELL; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; MICE; MICE, TRANSGENIC; NEUROFIBRILLARY TANGLES; NEURONS; PLAQUE, AMYLOID;

EID: 77954319047     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710791556168     Document Type: Article

References (97)

1. Newell, K.L.; Hyman, B.T.; Growdon, J.H.; Hedley-Whyte, E.T. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J. Neuropathol. Exp. Neurol., 1999, 58(11), 1147-1155.
2. Glenner, G.G.; Wong, C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun., 1984, 120(3), 885-890.
3. Nunan, J.; Small, D.H. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett., 2000, 483(1), 6-10.
4. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81(2), 741-766.
5. Selkoe, D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res., 2008, 192(1), 106-113.
6. Nicoll, J.A.; Yamada, M.; Frackowiak, J.; Mazur-Kolecka, B.; Weller, R.O. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol. Aging, 2004, 25(5), 589-597.
7. Rensink, A.A.; de Waal, R.M.; Kremer, B.; Verbeek, M.M. Pathogenesis of cerebral amyloid angiopathy. Brain Res. Brain Res. Rev., 2003, 43(2), 207-223.
8. Levy, E.; Carman, M.D.; Fernandez-Madrid, I.J.; Power, M.D.; Lieberburg, I.; van Duinen, S.G.; Bots, G.T.; Luyendijk, W.; Frangione, B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science, 1990, 248(4959), 1124-1126.
9. Yamada, M.; Itoh, Y.; Shintaku, M.; Kawamura, J.; Jensson, O.; Thorsteinsson, L.; Suematsu, N.; Matsushita, M.; Otomo, E. Immune reactions associated with cerebral amyloid angiopathy. Stroke, 1996, 27(7), 1155-1162.
10. Greenberg, S.M.; Shin, Y.; Grabowski, T.J.; Cooper, G.E.; Rebeck, G.W.; Iglesias, S.; Chapon, F.; Tournier-Lasserve, E.; Baron, J.C. Hemorrhagic stroke associated with the Iowa amyloid precursor protein mutation. Neurology, 2003, 60(6), 1020-1022.
11. Pfeifer, L.A.; White, L.R.; Ross, G.W.; Petrovitch, H.; Launer, L.J. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology, 2002, 58(11), 1629-1634.
12. Binder, L.I.; Guillozet-Bongaarts, A.L.; Garcia-Sierra, F.; Berry, R.W. Tau, tangles, and Alzheimer's disease. Biochim. Biophys. Acta, 2005, 1739(2-3), 216-223.
13. Mudher, A.; Shepherd, D.; Newman, T.A.; Mildren, P.; Jukes, J.P.; Squire, A.; Mears, A.; Drummond, J.A.; Berg, S.; MacKay, D.; Asuni, A.A.; Bhat, R.; Lovestone, S. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol. Psychiatry, 2004, 9(5), 522-530.
14. Cleveland, D.W.; Hwo, S.Y.; Kirschner, M.W. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J. Mol. Biol., 1977, 116(2), 207-225.
15. Weingarten, M.D.; Lockwood, A.H.; Hwo, S.Y.; Kirschner, M.W. A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA, 1975, 72(5), 1858-1862.
16. Biernat, J.; Mandelkow, E.M.; Schroter, C.; Lichtenberg-Kraag, B.; Steiner, B.; Berling, B.; Meyer, H.; Mercken, M.; Vandermeeren, A.; Goedert, M.; Mandelkow, E. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine- proline motifs upstream of the microtubule binding region. EMBO J., 1992, 11(4), 1593-1597.
17. Iqbal, K.; Alonso, A.C.; Gong, C.X.; Khatoon, S.; Singh, T.J.; Grundke-Iqbal, I. Mechanism of neurofibrillary degeneration in Alzheimer's disease. Mol. Neurobiol., 1994, 9(1-3), 119-123.
18. Wang, J.Z.; Grundke-Iqbal, I.; Iqbal, K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci., 2007, 25(1), 59-68.
19. Tanzi, R.E.; Kovacs, D.M.; Kim, T.W.; Moir, R.D.; Guenette, S.Y.; Wasco, W. The gene defects responsible for familial Alzheimer's disease. Neurobiol. Dis., 1996, 3(3), 159-168.
20. Corder, E.H.; Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.E.; Gaskell, P.C.; Small, G.W.; Roses, A.D.; Haines, J.L.; Pericak- Vance, M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 1993, 261(5123), 921-923.
21. Hutton, M.; Hardy, J. The presenilins and Alzheimer's disease. Hum. Mol. Genet., 1997, 6(10), 1639-1646.
22. Jankowsky, J.L.; Fadale, D.J.; Anderson, J.; Xu, G.M.; Gonzales, V.; Jenkins, N.A.; Copeland, N.G.; Lee, M.K.; Younkin, L.H.; Wagner, S.L.; Younkin, S.G.; Borchelt, D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet., 2004, 13(2), 159-170.
23. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356.
24. Hardy, J.A.; Higgins, G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256(5054), 184-185.
25. Kertesz, A. Clinical features and diagnosis of frontotemporal dementia. Front. Neurol. Neurosci., 2009, 24, 140-148.
26. Goedert, M. Tau gene mutations and their effects. Mov. Disord., 2005, 20(Suppl 12), S45-S52.
27. Neumann, M.; Tolnay, M.; Mackenzie, I.R. The molecular basis of frontotemporal dementia. Expert Rev. Mol. Med., 2009, 11, e23.
28. Games, D.; Adams, D.; Alessandrini, R.; Barbour, R.; Berthelette, P.; Blackwell, C.; Carr, T.; Clemens, J.; Donaldson, T.; Gillespie, F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature, 1995, 373(6514), 523-527.
29. Hsiao, K.; Chapman, P.; Nilsen, S.; Eckman, C.; Harigaya, Y.; Younkin, S.; Yang, F.; Cole, G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science, 1996, 274(5284), 99-102.
30. Chishti, M.A.; Yang, D.S.; Janus, C.; Phinney, A.L.; Horne, P.; Pearson, J.; Strome, R.; Zuker, N.; Loukides, J.; French, J.; Turner, S.; Lozza, G.; Grilli, M.; Kunicki, S.; Morissette, C.; Paquette, J.; Gervais, F.; Bergeron, C.; Fraser, P.E.; Carlson, G.A.; George- Hyslop, P.S.; Westaway, D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem., 2001, 276(24), 21562-21570.
31. Sturchler-Pierrat, C.; Abramowski, D.; Duke, M.; Wiederhold, K.H.; Mistl, C.; Rothacher, S.; Ledermann, B.; Burki, K.; Frey, P.; Paganetti, P.A.; Waridel, C.; Calhoun, M.E.; Jucker, M.; Probst, A.; Staufenbiel, M.; Sommer, B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA, 1997, 94(24), 13287-13292.
32. Dewachter, I.; van Dorpe, J.; Spittaels, K.; Tesseur, I.; Van Den Haute, C.; Moechars, D.; Van Leuven, F. Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp. Gerontol., 2000, 35(6-7), 831-841.
33. Herzig, M.C.; Van Nostrand, W.E.; Jucker, M. Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol., 2006, 16(1), 40-54.
34. Herzig, M.C.; Winkler, D.T.; Burgermeister, P.; Pfeifer, M.; Kohler, E.; Schmidt, S.D.; Danner, S.; Abramowski, D.; Sturchler- Pierrat, C.; Burki, K.; van Duinen, S.G.; Maat-Schieman, M.L.; Staufenbiel, M.; Mathews, P.M.; Jucker, M. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci., 2004, 7(9), 954-960.
35. Davis, J.; Xu, F.; Deane, R.; Romanov, G.; Previti, M.L.; Zeigler, K.; Zlokovic, B.V.; Van Nostrand, W.E. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem., 2004, 279(19), 20296-20306.
36. Krishnaswamy, S.; Verdile, G.; Groth, D.; Kanyenda, L.; Martins, R.N. The structure and function of Alzheimer's gamma secretase enzyme complex. Crit. Rev. Clin. Lab. Sci., 2009, 46(5-6), 282-301.
37. Duff, K.; Eckman, C.; Zehr, C.; Yu, X.; Prada, C.M.; Perez-Tur, J.; Hutton, M.; Buee, L.; Harigaya, Y.; Yager, D.; Morgan, D.; Gordon, M.N.; Holcomb, L.; Refolo, L.; Zenk, B.; Hardy, J.; Younkin, S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature, 1996, 383(6602), 710-713.
38. Holcomb, L.; Gordon, M.N.; McGowan, E.; Yu, X.; Benkovic, S.; Jantzen, P.; Wright, K.; Saad, I.; Mueller, R.; Morgan, D.; Sanders, S.; Zehr, C.; O'Campo, K.; Hardy, J.; Prada, C.M.; Eckman, C.; Younkin, S.; Hsiao, K.; Duff, K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med., 1998, 4(1), 97-100.
39. Holcomb, L.A.; Gordon, M.N.; Jantzen, P.; Hsiao, K.; Duff, K.; Morgan, D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav. Genet., 1999, 29(3), 177-185.
40. Borchelt, D.R.; Ratovitski, T.; van Lare, J.; Lee, M.K.; Gonzales, V.; Jenkins, N.A.; Copeland, N.G.; Price, D.L.; Sisodia, S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron, 1997, 19(4), 939-945.
41. Lewis, J.; McGowan, E.; Rockwood, J.; Melrose, H.; Nacharaju, P.; van, S.M.; Gwinn-Hardy, K.; Paul, M.M.; Baker, M.; Yu, X.; Duff, K.; Hardy, J.; Corral, A.; Lin, W.L.; Yen, S.H.; Dickson, D.W.; Davies, P.; Hutton, M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet., 2000, 25(4), 402-405.
42. Santacruz, K.; Lewis, J.; Spires, T.; Paulson, J.; Kotilinek, L.; Ingelsson, M.; Guimaraes, A.; DeTure, M.; Ramsden, M.; McGowan, E.; Forster, C.; Yue, M.; Orne, J.; Janus, C.; Mariash, A.; Kuskowski, M.; Hyman, B.; Hutton, M.; Ashe, K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science, 2005, 309(5733), 476-481.
43. Oddo, S.; Caccamo, A.; Shepherd, J.D.; Murphy, M.P.; Golde, T.E.; Kayed, R.; Metherate, R.; Mattson, M.P.; Akbari, Y.; Laferla, F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 2003, 39(3), 409-421.
44. Oddo, S.; Caccamo, A.; Kitazawa, M.; Tseng, B.P.; Laferla, F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging, 2003, 24(8), 1063-1070.
45. Oddo, S.; Caccamo, A.; Tran, L.; Lambert, M.P.; Glabe, C.G.; Klein, W.L.; Laferla, F.M. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J. Biol. Chem., 2006, 281(3), 1599-1604.
46. Morrissette, D.A.; LaFerla, F.M. Stereological quantification of neuronal cells in the 3XTg-AD mice. SFN 2007 Annual Meeting 2007.
47. Weinberg, J.B.; Misukonis, M.A.; Shami, P.J.; Mason, S.N.; Sauls, D.L.; Dittman, W.A.; Wood, E.R.; Smith, G.K.; McDonald, B.; Bachus, K.E. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood, 1995, 86(3), 1184-1195.
48. Colton, C.A.; Wilcock, D.M.; Wink, D.A.; Davis, J.; Van Nostrand, W.E.; Vitek, M.P. The Effects of nos2 gene deletion on mice expressing mutated human AbetaPP. J. Alzheimers Dis., 2008, 15(4), 571-587.
49. Colton, C.A.; Vitek, M.P.; Wink, D.A.; Xu, Q.; Cantillana, V.; Previti, M.L.; Van Nostrand, W.E.; Weinberg, J.B.; Dawson, H. NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2006, 103(34), 12867-12872.
50. Wilcock, D.M.; Lewis, M.R.; Van Nostrand, W.E.; Davis, J.; Previti, M.L.; Gharkholonarehe, N.; Vitek, M.P.; Colton, C.A. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J. Neurosci., 2008, 28(7), 1537-1545.
51. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffin, W.S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; O'Banion, M.K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F.L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T. Inflammation and Alzheimer's disease. Neurobiol. Aging, 2000, 21(3), 383-421.
52. Maier, M.; Peng, Y.; Jiang, L.; Seabrook, T.J.; Carroll, M.C.; Lemere, C.A. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci., 2008, 28(25), 6333-6341.
53. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400(6740), 173-177.
54. Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, C.; Hardy, J.; Duff, K.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; Connor, K.; Hatcher, J.; Hope, C.; Gordon, M.; Arendash, G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408(6815), 982-985.
55. Janus, C.; Pearson, J.; McLaurin, J.; Mathews, P.M.; Jiang, Y.; Schmidt, S.D.; Chishti, M.A.; Horne, P.; Heslin, D.; French, J.; Mount, H.T.; Nixon, R.A.; Mercken, M.; Bergeron, C.; Fraser, P.E.; St George-Hyslop, P.; Westaway, D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 2000, 408(6815), 979-982.
56. Wilcock, D.M.; DiCarlo, G.; Henderson, D.; Jackson, J.; Clarke, K.; Ugen, K.E.; Gordon, M.N.; Morgan, D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci., 2003, 23(9), 3745-3751.
57. Wilcock, D.M.; Munireddy, S.K.; Rosenthal, A.; Ugen, K.E.; Gordon, M.N.; Morgan, D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol. Dis., 2004, 15(1), 11-20.
58. Bacskai, B.J.; Kajdasz, S.T.; Christie, R.H.; Carter, C.; Games, D.; Seubert, P.; Schenk, D.; Hyman, B.T. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med., 2001, 7(3), 369-372.
59. Bacskai, B.J.; Kajdasz, S.T.; McLellan, M.E.; Games, D.; Seubert, P.; Schenk, D.; Hyman, B.T. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci., 2002, 22(18), 7873-7878.
60. Solomon, B.; Koppel, R.; Frankel, D.; Hanan-Aharon, E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA, 1997, 94(8), 4109-4112.
61. DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Dodart, J.C.; Paul, S.M.; Holtzman, D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2001, 98(15), 8850-8855.
62. Wilcock, D.M.; Rojiani, A.; Rosenthal, A.; Levkowitz, G.; Subbarao, S.; Alamed, J.; Wilson, D.; Wilson, N.; Freeman, M.J.; Gordon, M.N.; Morgan, D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci., 2004, 24(27), 6144-6151.
63. Vasilevko, V.; Xu, F.; Previti, M.L.; Van Nostrand, W.E.; Cribbs, D.H. Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. J. Neurosci., 2007, 27(49), 13376-13383.
64. Oddo, S.; Billings, L.; Kesslak, J.P.; Cribbs, D.H.; Laferla, F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 2004, 43(3), 321-332.
65. Wilcock, D.M.; Gharkholonarehe, N.; Van Nostrand, W.E.; Davis, J.; Vitek, M.P.; Colton, C.A. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J. Neurosci., 2009, 29(25), 7957-7965.
66. Nicoll, J.A.; Barton, E.; Boche, D.; Neal, J.W.; Ferrer, I.; Thompson, P.; Vlachouli, C.; Wilkinson, D.; Bayer, A.; Games, D.; Seubert, P.; Schenk, D.; Holmes, C. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol., 2006, 65(11), 1040-1048.
67. Nicoll, J.A.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H.; Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med., 2003, 9(4), 448-452.
68. Ferrer, I.; Boada, R.M.; Sanchez Guerra, M.L.; Rey, M.J.; Costa- Jussa, F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol., 2004, 14(1), 11-20.
69. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372(9634), 216-223.
70. Pfeifer, M.; Boncristiano, S.; Bondolfi, L.; Stalder, A.; Deller, T.; Staufenbiel, M.; Mathews, P.M.; Jucker, M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science, 2002, 298(5597), 1379.
71. Wilcock, D.M.; Rojiani, A.; Rosenthal, A.; Subbarao, S.; Freeman, M.J.; Gordon, M.N.; Morgan, D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation, 2004, 1(1), 24.
72. Schroeter, S.; Khan, K.; Barbour, R.; Doan, M.; Chen, M.; Guido, T.; Gill, D.; Basi, G.; Schenk, D.; Seubert, P.; Games, D. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci., 2008, 28(27), 6787-6793.
73. Racke, M.M.; Boone, L.I.; Hepburn, D.L.; Parsadainian, M.; Bryan, M.T.; Ness, D.K.; Piroozi, K.S.; Jordan, W.H.; Brown, D.D.; Hoffman, W.P.; Holtzman, D.M.; Bales, K.R.; Gitter, B.D.; May, P.C.; Paul, S.M.; DeMattos, R.B. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci., 2005, 25(3), 629-636.
74. Wilcock, D.M.; Jantzen, P.T.; Li, Q.; Morgan, D.; Gordon, M.N. Amyloid-beta vaccination, but not nitro-nonsteroidal anti- inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience, 2007, 144(3), 950-960.
75. Grundman, M.; Black, R. Clinical Trials of Bapineuzumab, A Beta- Amyloid-Targeted Immunotherapy in Patients with Mild to Moderate Alzheimer's Disease. In 2008 International Conference on Alzheimer's Disease, Chicago, IL, 2008, pp. 3-5.
76. Boche, D.; Zotova, E.; Weller, R.O.; Love, S.; Neal, J.W.; Pickering, R.M.; Wilkinson, D.; Holmes, C.; Nicoll, J.A. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain, 2008, 131(Pt 12), 3299-3310.
77. Szekely, C.A.; Thorne, J.E.; Zandi, P.P.; Ek, M.; Messias, E.; Breitner, J.C.; Goodman, S.N. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review.
78. Mackenzie, I.R.; Munoz, D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology, 1998, 50(4), 986-990.
79. Stewart, W.F.; Kawas, C.; Corrada, M.; Metter, E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology, 1997, 48(3), 626-632.
80. Vitek, M.P.; Brown, C.M.; Colton, C.A. APOE genotype-specific differences in the innate immune response. Neurobiol. Aging, 2009, 30(9), 1350-1360.
81. Morihara, T.; Teter, B.; Yang, F.; Lim, G.P.; Boudinot, S.; Boudinot, F.D.; Frautschy, S.A.; Cole, G.M. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1- antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. Neuropsychopharmacology, 2005, 30(6), 1111-1120.
82. Heneka, M.T.; Sastre, M.; Dumitrescu-Ozimek, L.; Hanke, A.; Dewachter, I.; Kuiperi, C.; O'Banion, K.; Klockgether, T.; Van Leuven, F.; Landreth, G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain, 2005, 128(Pt 6), 1442-1453.
83. Weggen, S.; Eriksen, J.L.; Das, P.; Sagi, S.A.; Wang, R.; Pietrzik, C.U.; Findlay, K.A.; Smith, T.E.; Murphy, M.P.; Bulter, T.; Kang, D.E.; Marquez-Sterling, N.; Golde, T.E.; Koo, E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 2001, 414(6860), 212-216.
84. Aisen, P.S.; Schafer, K.A.; Grundman, M.; Pfeiffer, E.; Sano, M.; Davis, K.L.; Farlow, M.R.; Jin, S.; Thomas, R.G.; Thal, L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA, 2003, 289(21), 2819-2826.
85. Thal, L.J.; Ferris, S.H.; Kirby, L.; Block, G.A.; Lines, C.R.; Yuen, E.; Assaid, C.; Nessly, M.L.; Norman, B.A.; Baranak, C.C.; Reines, S.A. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology, 2005, 30(6), 1204-1215.
86. Meinert, C.L.; McCaffrey, L.D.; Breitner, J.C. Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimers Dement., 2009, 5(2), 93-104.
87. Roberds, S.L.; Anderson, J.; Basi, G.; Bienkowski, M.J.; Branstetter, D.G.; Chen, K.S.; Freedman, S.B.; Frigon, N.L.; Games, D.; Hu, K.; Johnson-Wood, K.; Kappenman, K.E.; Kawabe, T.T.; Kola, I.; Kuehn, R.; Lee, M.; Liu, W.; Motter, R.; Nichols, N.F.; Power, M.; Robertson, D.W.; Schenk, D.; Schoor, M.; Shopp, G.M.; Shuck, M.E.; Sinha, S.; Svensson, K.A.; Tatsuno, G.; Tintrup, H.; Wijsman, J.; Wright, S.; McConlogue, L. BACE knockout mice are healthy despite lacking the primary beta- secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet., 2001, 10(12), 1317-1324.
88. Shen, J.; Bronson, R.T.; Chen, D.F.; Xia, W.; Selkoe, D.J.; Tonegawa, S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell, 1997, 89(4), 629-639.
89. Laird, F.M.; Cai, H.; Savonenko, A.V.; Farah, M.H.; He, K.; Melnikova, T.; Wen, H.; Chiang, H.C.; Xu, G.; Koliatsos, V.E.; Borchelt, D.R.; Price, D.L.; Lee, H.K.; Wong, P.C. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci., 2005, 25(50), 11693-11709.
90. McConlogue, L.; Buttini, M.; Anderson, J.P.; Brigham, E.F.; Chen, K.S.; Freedman, S.B.; Games, D.; Johnson-Wood, K.; Lee, M.; Zeller, M.; Liu, W.; Motter, R.; Sinha, S. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J. Biol. Chem., 2007, 282(36), 26326-26334.
91. Dovey, H.F.; John, V.; Anderson, J.P.; Chen, L.Z.; de Saint Andrieu, P.; Fang, L.Y.; Freedman, S.B.; Folmer, B.; Goldbach, E.; Holsztynska, E.J.; Hu, K.L.; Johnson-Wood, K.L.; Kennedy, S.L.; Kholodenko, D.; Knops, J.E.; Latimer, L.H.; Lee, M.; Liao, Z.; Lieberburg, I.M.; Motter, R.N.; Mutter, L.C.; Nietz, J.; Quinn, K.P.; Sacchi, K.L.; Seubert, P.A.; Shopp, G.M.; Thorsett, E.D.; Tung, J.S.; Wu, J.; Yang, S.; Yin, C.T.; Schenk, D.B.; May, P.C.; Altstiel, L.D.; Bender, M.H.; Boggs, L.N.; Britton, T.C.; Clemens, J.C.; Czilli, D.L.; Dieckman-McGinty, D.K.; Droste, J.J.; Fuson, K.S.; Gitter, B.D.; Hyslop, P.A.; Johnstone, E.M.; Li, W.Y.; Little, S.P.; Mabry, T.E.; Miller, F.D.; Audia, J.E. Functional gamma- secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem., 2001, 76(1), 173-181.
92. Milano, J.; McKay, J.; Dagenais, C.; Foster-Brown, L.; Pognan, F.; Gadient, R.; Jacobs, R.T.; Zacco, A.; Greenberg, B.; Ciaccio, P.J. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci., 2004, 82(1), 341-358.
93. Siemers, E.R.; Quinn, J.F.; Kaye, J.; Farlow, M.R.; Porsteinsson, A.; Tariot, P.; Zoulnouni, P.; Galvin, J.E.; Holtzman, D.M.; Knopman, D.S.; Satterwhite, J.; Gonzales, C.; Dean, R.A.; May, P.C. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology, 2006, 66(4), 602-604.
94. Manji, H.K.; Moore, G.J.; Chen, G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol. Psychiatry, 1999, 46(7), 929-940.
95. Perez, M.; Hernandez, F.; Lim, F.; Diaz-Nido, J.; Avila, J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis., 2003, 5(4), 301-308.
96. Noble, W.; Planel, E.; Zehr, C.; Olm, V.; Meyerson, J.; Suleman, F.; Gaynor, K.; Wang, L.; LaFrancois, J.; Feinstein, B.; Burns, M.; Krishnamurthy, P.; Wen, Y.; Bhat, R.; Lewis, J.; Dickson, D.; Duff, K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA, 2005, 102(19), 6990-6995.
97. Caccamo, A.; Oddo, S.; Tran, L.X.; LaFerla, F.M. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol., 2007, 170(5), 1669-1675.